ASG - Aurora Spine Has Three Shots On Goal

• Aurora Spine has three products, DEXA, SILO, and ZIP that have been met with early strong market interest evidenced by sequential quarterly revenue growth exceeding 20% over the last year.
• DEXA is the first commercially available technology that provides customized devices matching an individual patient's bone density. The technology can be licensed for procedures beyond Aurora's core competency.
• SILO and ZIP are high-profit margin products devices for minimally invasive surgery on an out-patient basis with insurance pre-approval.
• The company is expecting that FDA clearance will be obtained shortly for two more revenue accelerators, the DEXA-L and the Silo TFX devices.
• The stock sells at a low multiple and should rerate as the company turns profitable, which I expect this year.

For further details see: